

# Davide Corti

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5170634/davide-corti-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

121  
papers

12,649  
citations

55  
h-index

112  
g-index

129  
ext. papers

19,719  
ext. citations

27.5  
avg, IF

6.53  
L-index

#	Paper	IF	Citations
121	Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. <i>Nature</i> , <b>2020</b> , 583, 290-294	39.4	1028
120	A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. <i>Science</i> , <b>2011</b> , 333, 850-6	33.3	891
119	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. <i>Cell</i> , <b>2020</b> , 183, 1024-1042.e21	56.2	601
118	Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. <i>Science</i> , <b>2016</b> , 353, 823-6	33.3	528
117	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , <b>2021</b> , 27, 717-726	50.5	497
116	Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. <i>Cell</i> , <b>2019</b> , 176, 1026-1039.e15	56.2	416
115	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , <b>2021</b> , 184, 2332-2347.e16	56.2	316
114	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. <i>Nature</i> , <b>2021</b> , 593, 136-141	50.4	376
113	Broadly neutralizing antiviral antibodies. <i>Annual Review of Immunology</i> , <b>2013</b> , 31, 705-42	34.7	351
112	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. <i>Nature</i> , <b>2021</b> , 599, 114-119	50.4	334
111	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. <i>Cell</i> , <b>2021</b> , 184, 1171-1187.e20	56.2	331
110	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <i>Science</i> , <b>2020</b> , 370, 950-957	33.3	314
109	A perspective on potential antibody-dependent enhancement of SARS-CoV-2. <i>Nature</i> , <b>2020</b> , 584, 353-363	50.4	289
108	Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. <i>Science</i> , <b>2016</b> , 351, 1339-42	33.3	280
107	SARS-like WIV1-CoV poised for human emergence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 3048-53	11.5	279
106	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>Cell Host and Microbe</i> , <b>2020</b> , 28, 475-485.e5	23.4	252
105	Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes. <i>Cell</i> , <b>2016</b> , 166, 596-608	56.2	228

104	Rapid development of broadly influenza neutralizing antibodies through redundant mutations. <i>Nature</i> , <b>2014</b> , 516, 418-22	50.4	219
103	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.. <i>Nature</i> , <b>2021</b> ,	50.4	204
102	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , <b>2021</b> , 373, 648-654	33.3	197
101	Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. <i>Nature</i> , <b>2013</b> , 501, 439-43	50.4	175
100	Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. <i>Cell Reports</i> , <b>2021</b> , 35, 109292	10.6	172
99	Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 10473-8	11.5	170
98	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. <i>Nature</i> , <b>2021</b> , 595, 707-712	50.4	168
97	Clonal dissection of the human memory B-cell repertoire following infection and vaccination. <i>European Journal of Immunology</i> , <b>2009</b> , 39, 1260-70	6.1	149
96	Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020 <b>2021</b> ,		142
95	Antibody-based assay discriminates Zika virus infection from other flaviviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 8384-8389	11.5	129
94	Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. <i>Journal of Virology</i> , <b>2008</b> , 82, 3220-35	6.6	128
93	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. <i>Nature</i> , <b>2021</b> , 597, 97-102	50.4	118
92	Platelet-derived growth factor- $\beta$ receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer. <i>Nature Microbiology</i> , <b>2016</b> , 1, 16082	26.6	115
91	Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , <b>2021</b> , 184, 3086-3108	56.2	108
90	Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70		106
89	A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens. <i>Nature</i> , <b>2016</b> , 529, 105-109	50.4	105
88	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	102
87	Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 17965-70	11.5	96

86	Tackling influenza with broadly neutralizing antibodies. <i>Current Opinion in Virology</i> , <b>2017</b> , 24, 60-69	7.5	95
85	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity.. <i>Nature</i> , <b>2022</b> ,	50.4	95
84	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , <b>2021</b> , 597, 103-108	50.4	94
83	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , <b>2021</b> , 596, 103-108	50.4	91
82	Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. <i>Nature Structural and Molecular Biology</i> , <b>2020</b> , 27, 942-949	17.6	89
81	A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential. <i>Cell</i> , <b>2017</b> , 171, 229-241	16.15	85
80	Broad betacoronavirus neutralization by a stem helix-specific human antibody. <i>Science</i> , <b>2021</b> , 373, 1109-1116	11.16	80
79	Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 946-55	7	79
78	The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2		72
77	Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement.. <i>Science</i> , <b>2022</b> , 375, eabn8652	33.3	71
76	SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies <b>2021</b> ,		69
75	After the pandemic: perspectives on the future trajectory of COVID-19. <i>Nature</i> , <b>2021</b> , 596, 495-504	50.4	68
74	Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. <i>PLoS Pathogens</i> , <b>2010</b> , 6, e1001195	7.6	67
73	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. <i>Science</i> , <b>2021</b> , eabl8506	33.3	65
72	Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. <i>Nature</i> , <b>2021</b> , 598, 342-347	50.4	63
71	Human monoclonal antibodies by immortalization of memory B cells. <i>Current Opinion in Biotechnology</i> , <b>2007</b> , 18, 523-8	11.4	62
70	SARS-CoV-2 immune evasion by variant B.1.427/B.1.429 <b>2021</b> ,		62
69	SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough		62

68	Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. <i>Nature Communications</i> , <b>2015</b> , 6, 7375	17.4	61
67	Influenza hemagglutinin membrane anchor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 10112-10117	11.5	61
66	The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity		53
65	Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis. <i>EMBO Molecular Medicine</i> , <b>2016</b> , 8, 407-21	12	51
64	Comparison of Four Serological Methods and Two Reverse Transcription-PCR Assays for Diagnosis and Surveillance of Zika Virus Infection. <i>Journal of Clinical Microbiology</i> , <b>2018</b> , 56,	9.7	50
63	Persistent Antibody Clonotypes Dominate the Serum Response to Influenza over Multiple Years and Repeated Vaccinations. <i>Cell Host and Microbe</i> , <b>2019</b> , 25, 367-376.e5	23.4	47
62	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> ,	50.4	44
61	Capsid protein structure in Zika virus reveals the flavivirus assembly process. <i>Nature Communications</i> , <b>2020</b> , 11, 895	17.4	43
60	Structural and functional analysis of a potent sarbecovirus neutralizing antibody <b>2020</b> ,		42
59	Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 12265-12270	11.5	41
58	Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. <i>Nature</i> , <b>2020</b> , 588, 485-490	50.4	40
57	SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies <b>2021</b> ,		39
56	Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant <i>Klebsiella pneumoniae</i> . <i>Nature Communications</i> , <b>2017</b> , 8, 1991	17.4	37
55	Antibody-guided vaccine design: identification of protective epitopes. <i>Current Opinion in Immunology</i> , <b>2016</b> , 41, 62-67	7.8	35
54	Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 9430-5	11.5	34
53	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 <b>2021</b> ,		34
52	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , <b>2021</b> , 184, 5432-5447.e16	56.2	34
51	Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. <i>Cell Host and Microbe</i> , <b>2019</b> , 26, 623-637.e8	23.4	33

50	Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants <b>2021</b> ,		31
49	Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells. <i>Microbiology Spectrum</i> , <b>2014</b> , 2,	8.9	30
48	Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. <i>Lancet Regional Health - Europe, The</i> , <b>2021</b> , 1, 100013		29
47	Protection of calves by a prefusion-stabilized bovine RSV F vaccine. <i>Npj Vaccines</i> , <b>2017</b> , 2, 7	9.5	27
46	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.. <i>Science</i> , <b>2022</b> , 375, eabm8143	33.3	23
45	SARS-CoV-2 Omicron spike mediated immune escape and tropism shift		23
44	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. <b>2021</b> ,		22
43	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses.. <i>Cell</i> , <b>2022</b> ,	56.2	21
42	Anti-LPS antibodies protect against <i>Klebsiella pneumoniae</i> by empowering neutrophil-mediated clearance without neutralizing TLR4. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	19
41	Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies		18
40	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <b>2021</b> ,		16
39	Alternative conformations of a major antigenic site on RSV F. <i>PLoS Pathogens</i> , <b>2019</b> , 15, e1007944	7.6	15
38	Therapeutic Administration of Broadly Neutralizing F16 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 865	8.4	14
37	Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody <b>2021</b> ,		14
36	Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein. <i>Nature Communications</i> , <b>2020</b> , 11, 596	17.4	13
35	A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery		13
34	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>SSRN Electronic Journal</i> , <b>2020</b> , 3606354	1	12
33	Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape <b>2021</b> ,		12

32	Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement		11
31	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies		10
30	Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 <b>2020</b> ,		10
29	Predicting the mutational drivers of future SARS-CoV-2 variants of concern.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabk3445	17.5	9
28	Discovery and Characterization of Spike N-Terminal Domain-Binding Aptamers for Rapid SARS-CoV-2 Detection. <i>Angewandte Chemie - International Edition</i> , <b>2021</b> , 60, 21211-21215	16.4	9
27	Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset. <i>Antiviral Research</i> , <b>2019</b> , 163, 70-74	10.8	8
26	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy.. <i>PLoS Pathogens</i> , <b>2022</b> , 18, e1010248	7.6	7
25	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry <b>2021</b> ,		7
24	Closing coronavirus spike glycoproteins by structure-guided design <b>2020</b> ,		7
23	A combination of two human monoclonal antibodies cures symptomatic rabies. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e12628	12	7
22	SARS-CoV-2 spike conformation determines plasma neutralizing activity. <b>2021</b> ,		6
21	Predicting the mutational drivers of future SARS-CoV-2 variants of concern		6
20	Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution		6
19	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy <b>2021</b> ,		5
18	Imprinted antibody responses against SARS-CoV-2 Omicron sublineages		5
17	AncesTree: An interactive immunoglobulin lineage tree visualizer. <i>PLoS Computational Biology</i> , <b>2020</b> , 16, e1007731	5	4
16	Exceptionally potent human monoclonal antibodies are effective for prophylaxis and treatment of tetanus in mice. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	3
15	Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains		3

14	Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines. <b>2022,</b>		3
13	ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies		3
12	Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail. <b>2022,</b>		2
11	Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0263328	3.7	2
10	Defective neutralizing antibody response to SARS-CoV-2 in vaccinated dialysis patients		2
9	Structure, receptor recognition and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein		
8	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains <b>2021,</b>		2
7	Discovery and Characterization of Spike N-Terminal Domain-Binding Aptamers for Rapid SARS-CoV-2 Detection. <i>Angewandte Chemie</i> , <b>2021</b> , 133, 21381-21385	3.6	1
6	Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy.. <i>Current Opinion in Virology</i> , <b>2022</b> , 53, 101204	7.5	0
5	Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells129-139		
4	AncesTree: An interactive immunoglobulin lineage tree visualizer <b>2020</b> , 16, e1007731		
3	AncesTree: An interactive immunoglobulin lineage tree visualizer <b>2020</b> , 16, e1007731		
2	AncesTree: An interactive immunoglobulin lineage tree visualizer <b>2020</b> , 16, e1007731		
1	AncesTree: An interactive immunoglobulin lineage tree visualizer <b>2020</b> , 16, e1007731		